entertainment -WSS

entertainment

author：focus 2025-09-29 20:00:07 - browse：2

Eli Lilly headquarters — Kristoffer Tripplaar/AP

SAN DIEGO – An experimental pill from Eli Lilly led to 14.7% weight loss on the highest dose in a 36-week trial, heating up the growing competition among drugmakers to develop an effective oral obesity therapy.

The mid-stage results for orforglipron match the estimates of 14-15% weight loss that Lilly gave in an investor call late last year. The full results, published Friday in the New England Journal of Medicine, were presented here to a packed conference room at the American Diabetes Association conference.

By the end of trial, the authors said, participants’ weight loss had not plateaued, suggesting potential for even greater weight loss over a longer treatment period.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Contact tracing may help avoid another lockdown. Can it work in the U.S.?

hotspot

WSS

Peter Marks talks Operation Warp Speed for Rare Diseases

Humana CEO Bruce Broussard to step down in 2024

New rules on organ donation and transplantation 'will bring chaos'

What to know about Saharan dust affecting the US and how it can affect health

How should state employee insurance handle Wegovy?

Contact tracing may help avoid another lockdown. Can it work in the U.S.?

leisure time

entertainment

hotspot

Supreme Court strikes down use of affirmative action

Caitlin Bernard's story shows physicians can't shy from advocacy

Medical records are filled with copy

A revolution in caring for preterm infants

Medical leaders decry Supreme Court decision on affirmative action

There’s no way to know how good AI health technologies are

Anesthesiologist group: stop taking Ozempic before surgery

Southern California school board OKs curriculum after Gov. Gavin Newsom threatened a $1.5M fine

Continuity nursing helped my family in our darkest PICU moments

Better Therapeutics data on benefit with GLP

explore

Death toll from an explosion and collapse of a Paris building in June climbs to 3

Organ transplantation is at a crossroads. Major reform is needed

Peter Marks talks Operation Warp Speed for Rare Diseases

STAT Readout Newsletter: Today in biotech, life science news

As Taiwan prepares for anti

European regulators recommend Amylyx's ALS drug be rejected

hotspot

hotspot

hotspot

hotspot